SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists

Landmark trials on diabetes control have shown variable results in terms of cardiovascular benefits, with the majority showing a favorable effect of glycemic control on microvascular and, more recently, macrovascular complications. However, some trials pointed out a CV hazard with tight diabetes mel...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelgadir, Elamin, Rashid, Fauzia, Bashier, Alaaeldin, Ali, Razan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031247/
https://www.ncbi.nlm.nih.gov/pubmed/29977418
http://dx.doi.org/10.14740/jocmr3467w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031247/
https://www.ncbi.nlm.nih.gov/pubmed/29977418
http://dx.doi.org/10.14740/jocmr3467w

Ejemplares similares